Imperial Oil Limited Common Stock vs Repligen Corporation Common Stock — how do they compare? Imperial Oil Limited Common Stock trades at $129.6 (market cap $62.22B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Imperial Oil Limited Common Stock is far larger — about 5.6× Repligen Corporation Common Stock's market cap, and Imperial Oil Limited Common Stock pays a 1.9% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals.
| IMO | RGEN | |
|---|---|---|
Market Cap | $62.22B | $11.14B |
Volume | 560,544 | 1,259,263 |
Sector | Energy | Health |
52-Week High | $138.33 | $194.57 |
52-Week Low | $83.72 | $102.87 |
Enterprise Value | $63.13B | $11.02B |
Dividend Yield | 1.9% | — |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →